Suspensions: Clinical Trials

79 trials of Suspensions, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

63 completed, 7 terminated, 4 withdrawn, 2 recruiting. 79 Phase 1, 11 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 179Completed 63, Terminated 7, Withdrawn 4, Recruiting 2, Active not recruiting 1, Not yet recruiting 1, Unknown 1
Phase 211Completed 6, Recruiting 2, Terminated 2, Withdrawn 1

Follow Suspensions: new trials by email Literature Review of Suspensions trials Research Report on Suspensions

Trials (filtered) newest first · largest first

All 79 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Radiation-Free Technique for Evaluating Renal Scarring (RAFTERS)
Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON] - Vesico-Ureteral Reflux
Phase 1Not yet recruitingBoston Children's Hospital702027-07-012026-07-22
A Study to Investigate the Relative Bioavailability and Food Effect of Tablet for Oral Suspension of Sonrotoclax in Healthy Adults
Sonrotoclax Tablet for Oral Suspension, Sonrotoclax Tablet - Healthy Volunteers
Phase 1CompletedBeOne Medicines122026-06-172026-10-23
A Study(Phase I)of GS3-007a Dry Suspension in Healthy Chinese Adults
GS3-007a for Suspension, Placebo GS3-007a for Suspension - Healthy Adults
Phase 1CompletedChangchun GeneScience Pharmaceutical Co., Ltd.322026-01-072026-11-05
Study on Sapropterin Dihydrochloride Oral Suspension in Healthy Subjects Under Fed Conditions
RLF-OD032 100 mg/mL oral suspension, Kuvan 100 MG Powder for Oral Solution - Bioequivalence
Phase 1CompletedAPR Applied Pharma Research s.a.422025-08-202026-04-28
A Study to Evaluate the Bioavailability of Two Specifications of Oral Deuremidevir Hydrobromide for Suspension
test formulation(T) 200 mg deuteriumremidvir hydrobromide for suspension, reference formulation(R) 100 mg deuteriumremidvir hydrobromide for suspension - Healthy Participants
Phase 1CompletedVigonvita Life Sciences182025-08-112025-11-21
Comparing the Availability of AQ280 in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation
AQ280 Capsule, AQ280 Tablet for Oral Suspension, Placebo Capsule - Eosinophilic Esophagitis
Phase 1CompletedAQILION AB92025-06-132026-06-01
Bioavailability of Stiripentol After Single Oral Dose of Capsule vs Suspension in Healthy Subjects (STILIQ)
Stiripentol capsule (Diacomit®), Stiripentol oral suspension (Diacomit®) - Dravet Syndrome, Epilepsy
Phase 1CompletedBiocodex242025-06-012025-09-16
Study to Assess Relative Bioavailability of GP681 Formulations in Healthy Chinese Male Subjects
GP681 tablet, GP681 Powder for Oral Suspension - Healthy Participants
Phase 1CompletedJiangxi Qingfeng Pharmaceutical Co. Ltd.362024-09-272025-03-14
A Relative Bioavailability Study With a Novel PanCytoVir™ Oral Suspension (100 mg/ml)
PanCytoVir™ 100 mg/mL oral suspension, Probenecid 500 mg - Relative Bioavailability
Phase 1CompletedTrippBio, Inc.142024-09-012024-11-21
Bioequivalence Study to Compare Bosentan 32 mg Dispersible Tablets Versus Tracleer® 32 mg Tablets
Bosentan Dispersible Tablets, Tracleer Tablet for Oral Suspension - Pulmonary Arterial Hypertension
Phase 1CompletedHumanis Saglık Anonim Sirketi322024-04-212024-07-03
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Deuremidevir Hydrobromide for Suspension
Deuremidevir Hydrobromide for Suspension, Deuremidevir Hydrobromide for Suspension Placebo - Respiratory Syncytial Virus Infections
Phase 1CompletedVigonvita Life Sciences242024-03-272024-10-01
Bioequivalence Assessment Between Two Perampanel Oral Suspension Formulations
Lepsiramp, 0.5 Mg/mL Oral Suspension, Fycompa, 0.5 Mg/mL Oral Suspension - Bioequivalence Study in Healthy Subjects
Phase 1CompletedAya Mohammed Abdel Magid Abdel Hamid262024-03-072025-08-20
Safety and Efficacy of MSC-EVs in the Prevention of BPD in Extremely Preterm Infants
Endotracheopulmonary Instillation, Suspension - Bronchopulmonary Dysplasia
Phase 1 / Phase 2RecruitingEXO Biologics S.A.2652023-12-282024-09-19
A Study to Evaluate the Bioavailability, Food Effect and Pharmacokinetics of Deuremidevir Hydrobromide for Suspension
Deuremidevir Hydrobromide for Suspension 100mg, Deuremidevir Hydrobromide for Suspension 300mg, Deuremidevir Hydrobromide for Suspension 25mg - Healthy Subjects
Phase 1CompletedVigonvita Life Sciences382023-07-092024-11-20
A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults
Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection, Candidate 1: PF-07915234: VZV modRNA Suspension for Injection, Candidate 2: PF-07921188: VZV modRNA Suspension for Injection - Shingles, Herpes Zoster Infection
Phase 1 / Phase 2TerminatedPfizer4842023-01-252026-05-04
Biological Response to Platelet-rich Plasma and Corticosteroid Injections
Triamcinolone Acetonide 40 mg/ml Inj, Susp, Platelet-rich plasma Inj - Knee Osteoarthritis
Phase 1 / Phase 2TerminatedUniversity of Missouri-Columbia232022-12-282025-06-25
Contrast Enhanced 3D Echocardiographic Quantification of Right Ventricular Volumes in Repaired CHD
Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON] - Tetralogy of Fallot, Pulmonary Insufficiency
Phase 1 / Phase 2CompletedNemours Children's Clinic252022-08-232026-04-27
QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors
M-CENK, Suspension for Infusion, Cryopreserved (M-CENK) (Cohort 2 part B), N-803 (Cohort 2 part B), Apheresis collection of MNCs (part A) - Metastatic Solid Tumor
Phase 1Active not recruitingImmunityBio, Inc.502021-06-212026-11-02
Study on the Human Bioequivalence of Oseltamivir Phosphate For Oral Suspension
Oseltamivir Phosphate For Oral Suspension/Tamiflu, Oseltamivir Phosphate For Oral Suspension - Healthy Subjects
Phase 1CompletedThe Affiliated Hospital of Qingdao University722021-05-132022-03-28
COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA
hAd5-S-Fusion+N-ETSD (Suspension for injection), hAd5-SFusion+ N-ETSD (Oral capsule) - Covid19
Phase 1TerminatedImmunityBio, Inc.282021-02-242024-10-15

Showing 20 of 79. Sign in to see all of them.

Conditions studied

Neoplasm Metastasis (4)  ·  Neoplasms (4)  ·  Bacterial Infections (2)  ·  Epilepsy (2)  ·  HIV Infections (2)  ·  Pulmonary Arterial Hypertension (2)  ·  Breast Neoplasms (1)  ·  Breast Neoplasms, Male (1)  ·  Bronchopulmonary Dysplasia (1)  ·  COVID-19 (1)  ·  Carcinoma, Renal Cell (1)  ·  Chickenpox (1)  ·  Cystic Fibrosis (1)  ·  Eosinophilic Esophagitis (1)  ·  Epilepsies, Myoclonic (1)

Sponsors

Teva Pharmaceuticals USA (6)  ·  Bayer (5)  ·  Sandoz (5)  ·  Pfizer (4)  ·  ImmunityBio, Inc. (3)  ·  Lakefront Biotherapeutics NV (3)  ·  Vigonvita Life Sciences (3)  ·  Actavis Inc. (2)  ·  AstraZeneca (2)  ·  Aziende Chimiche Riunite Angelini Francesco S.p.A (2)  ·  GlaxoSmithKline (2)  ·  Janssen R&D Ireland (2)  ·  Janssen Research & Development, LLC (2)  ·  Medicines for Malaria Venture (2)  ·  Merck Sharp & Dohme LLC (2)

Countries

United States (26)  ·  United Kingdom (10)  ·  Canada (7)  ·  China (7)  ·  Belgium (5)  ·  Brazil (4)  ·  Australia (3)  ·  France (3)  ·  Germany (3)  ·  South Africa (3)  ·  Botswana (2)  ·  India (2)  ·  Italy (2)  ·  Jordan (2)  ·  Netherlands (2)

Top investigators

Magdy L. Shenouda, M.D. (2)  ·  Milko Radicioni, MD (2)  ·  Paul Y. Tam,, MD (2)  ·  Soran Hong, M.D. (2)  ·  Steven Herrmann, M.D. (2)  ·  Xiaojie Wu (2)  ·  Abdullah Hiyari, MD (1)  ·  Alan Jobe, MD, Ph.D (1)  ·  Andrew Wiznia, M.D. (1)  ·  Andrew Wiznia, MD (1)

Results publications

PMID 15039276, PMID 18587624, PMID 23559821, PMID 24145879, PMID 25035839, PMID 28287489, PMID 29266308, PMID 30527329, PMID 31012984, PMID 31901394, PMID 31972249, PMID 32551947, PMID 32682946, PMID 33340343, PMID 33710976, PMID 34379314, PMID 34505846, PMID 34694878, PMID 34814185, PMID 34817414, PMID 34945097, PMID 35489377, PMID 36045513, PMID 37310224, PMID 38279383, PMID 40560938, PMID 41249688, PMID 42731017

NIH funding

2015 (5), 2014 (2), 2016 (1), 2017 (1), 2018 (1), 2023 (1)